RESEARKA

The question of whether lipid-lowering therapies can extend human healthspan has gained urgency as populations age and cardiovascular disease remains the leading cause of death worldwide. PCSK9 inhibitors, a class of monoclonal antibodies that dramatically reduce low-density lipoprotein cholesterol, have been proposed as candidates for lifespan extension beyond their primary cardiovascular indications. The rationale linking PCSK9 inhibitors longevity rests on the observation that sustained LDL-C reduction may attenuate atherosclerotic burden and vascular aging, processes closely intertwined with functional decline in older adults (Kakaletsis 2024). Yet the clinical stakes are high: if these agents offer only narrow cardioprotection without broader geroprotective effects, the cost-benefit calculus for widespread deployment in aging populations remains uncertain. Early pharmacovigilance data suggest a largely acceptable safety profile (Zhang 2015), but whether safety in middle-aged cardiovascular cohorts translates to tolerability in the oldest-old is unproven. The PCSK9 inhibitors longevity hypothesis therefore represents a testable intersection of cardiovascular medicine and geroscience that demands rigorous evidence synthesis.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023